Dabigatran antidote idarucizumab has come to clinical practice

1 February 2016

journal article
Published by Czech Society of Cardiology in Cor et Vasa

Vol. 58 (1), e1-e3
https://doi.org/10.1016/j.crvasa.2016.02.001

Abstract

A first antidote for novel (non-warfarin) oral anticoagulants (NOAC) has come to clinical practice. Idarucizumab (Praxbind®, Boehringer-Ingelheim) was approved in 2015 by both European and US regulatory authorities and since January 2016 has been available in Europe, including the Czech Republic.

Keywords

NOAC
WARFARIN
ANTIDOTE IDARUCIZUMAB
DABIGATRAN ANTIDOTE
CZECH REPUBLIC
ORAL ANTICOAGULANTS

This publication has 1 reference indexed in Scilit:

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology
Cor et Vasa, 2016

Cited by 1 article